Osteoporosis Drugs Market
Osteoporosis Drugs market share with predicted implications of corona impact, brand share analysis, lockdown impact assessment, deep-dive competition analysis, market size and historical value analysis
Osteoporosis Drugs Market to Expands in Line With Research & Development Activities; North America Holds Major Market Share
- Report code : PMRREP2983 |
- Industry : Life Sciences & Transformational Health |
- Published On : Jun-2015 |
- Pages : 71 Pages |
- Format :
The global osteoporosis drugs market is projected to exhibit sluggish growth by the end of 2025 with escalating demand for these drugs across the globe for the treatment of ailments such as prophylaxis. The wide range of pipeline drugs are expected to create new revenue prospects in the market. Growing osteoporosis conditions bred by the sedentary lifestyle is expected to drive the adoption rate of these drugs in the coming years.
COVID-19 pandemic is expected to reduce the demand for a brief time period owing to a reduction in reported cases of ailments. The market is expected to witness a surge in demand with growing relaxations in people's movements.North America is projected to hold major market share by the end of the forecast period owing to enhanced research & development activities and high medical standards. Burgeoning investments are expected to impart a high growth rate to the osteoporosis market in the Asia Pacific, creating new revenue pockets to the manufacturers.
The market players are adopting collaborative strategies to sustain market competition. The manufactures are investing in research and development to introduce innovative products in the market. Established players in the market include Novo Nordisk A/S, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Novartis AG.
The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market. However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits growth of the market.
The osteoporosis drugs market is anticipated to grow from an estimated US$11,226.1 Mn in 2015 to account for US$14,786.7 Mn by 2022 at a CAGR of 4.0% during the forecast period.North America is the largest market for osteoporosis drugs, with bisphosphonates being the most popular type of osteoporosis drugs. Asia-Pacific is the fastest growing region in terms of revenue while RANK ligand inhibitors are the fastest growing type of osteoporosis drugs.
Bisphosphonates are the most commonly prescribed medication for treatment and prevention of osteoporosis. The global bisphosphonates drugs market is expected to grow from an estimated US$5,482.6 Mn in 2015 to US$7,342.2 Mn by 2022 at a CAGR of 4.3% during the forecast period.
Osteoporosis is a progressive, skeletal disease, leading to fragile and abnormally porous bones. It is characterized by decrease in bone density, strength, and micro-architectural deterioration of bone tissue resulting in thinning or weakening of bones with an increased propensity of fractures. Primary and secondary osteoporosis are the major types of osteoporosis. Some of the factors leading to osteoporosis are genetic factor, aging, lack of calcium and vitamin D, smoking, lack of exercise, low body weight, excessive alcohol consumption, history of rheumatoid arthritis, menopause, and certain medication. Osteoporosis can be diagnosed using X-ray and can be confirmed by bone density scan. Dual energy X-ray absorptiometry (DEXA) is the common bone density test used to measure the density of bones. Treatment for osteoporosis begins with a change in lifestyle and diet. It can be prevented and treated with the help of calcium and vitamin D supplements, exercise, and osteoporosis medications. Prevalence of osteoporosis is high among people aged 60 years and above. Moreover, estrogen plays a vital role in regulating the bone growth process in women. Post menopause, bone breakdown outpaces the building of new bone matter. The rate of bone loss in women increases after menopause, leading to the threat of developing osteoporosis.
North America is the largest market for osteoporosis drugs due to increasing geriatric population, growing investment in R&D for the discovery of innovative drugs, and rising prevalence of lifestyle-associated diseases in the region. Asia-Pacific is expected to exhibit high growth rates over the following five years in the global osteoporosis drugs market. China and India are expected to be the fastest-growing markets for osteoporosis drugs in Asia Pacific. Some of the key driving forces for the osteoporosis drugs market in emerging countries are rising geriatric population, a large pool of patients, changing lifestyles, increasing healthcare expenditure, and growing awareness about osteoporosis care in these regions.
Rising geriatric population, changing lifestyle impinging bone health, and increasing prevalence of osteoporosis in post-menopausal women are some of the factors driving the growth of the global osteoporosis drugs market. In addition, increasing awareness about osteoporosis care and growing investments in R&D for the discovery of innovative drugs are also fueling the growth of the market. On the other hand, side effects and complications such as irritable bowel syndrome, nausea, and ulcers in stomach or esophagus, associated with osteoporosis drugs and patent expiration of osteoporosis drugs are inhibiting growth of the global osteoporosis drugs market.
This report provides in-depth analysis and estimation of the osteoporosis drugs market for 2015– 2022, considering 2014 as the base year for calculation. Moreover, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report.
Key segments covered in this report are:
- By drugs type
- Bisphosphonates
- Parathyroid Hormone Therapy Drugs
- Calcitonin
- Selective Estrogen Receptors Modulators (SERMs)
- RANK Ligand Inhibitors
Key geographies evaluated in this report are:
- North America
- U.S.
- Europe
- France, Germany, and the UK
- Rest of Europe
- APAC
- China
- India
- Japan
- Rest of Asia Pacific
Key features of this report
- Drivers, restraints, and challenges shaping the osteoporosis drugs market dynamics
- Latest innovations and key events in the market
- Analysis of business strategies of the top players in the market
- Osteoporosis drugs market estimates and forecasts
Companies covered in Osteoporosis Drugs Market Report
Top companies profiled in this report are:
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Merck & Co, Inc.
- Novartis AG
- Amgen, Inc.
- Novo Nordisk A/S
- Actavis plc
- Pfizer, Inc.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd
- Other
